EP0620739A1 - Procede de traitement de l'inflammation dependante du facteur necrosant des tumeurs malignes (tnf) a l'aide d'antagonistes dudit tnf - Google Patents

Procede de traitement de l'inflammation dependante du facteur necrosant des tumeurs malignes (tnf) a l'aide d'antagonistes dudit tnf

Info

Publication number
EP0620739A1
EP0620739A1 EP93921562A EP93921562A EP0620739A1 EP 0620739 A1 EP0620739 A1 EP 0620739A1 EP 93921562 A EP93921562 A EP 93921562A EP 93921562 A EP93921562 A EP 93921562A EP 0620739 A1 EP0620739 A1 EP 0620739A1
Authority
EP
European Patent Office
Prior art keywords
tnfr
ser
pro
ala
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93921562A
Other languages
German (de)
English (en)
Other versions
EP0620739A4 (en
Inventor
Craig A. Smith
Cindy A. Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0620739(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of EP0620739A1 publication Critical patent/EP0620739A1/fr
Publication of EP0620739A4 publication Critical patent/EP0620739A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • TNF proteins initiate their biological effect on cells by binding to specific TNF receptor (TNFR ⁇ proteins expressed on the plasma membrane of a TNF-responsive cell.
  • TNF receptor TNF receptor
  • TNFI TNF receptor
  • Type II TNFR TNFRI and TNFRII each bind to both TNF ⁇ and TNF ⁇ .
  • TNF antagonists have yet to be identified.
  • TNFR with or without associated native-pattern glycosylation may also be used.
  • TNFR expressed in yeast or mammalian expression systems e.g., COS-7 cells, may be similar or slightly different in molecular weight and glycosylation pattern than the native molecules, depending upon the expression system.
  • Expression of TNFR DNAs in bacteria such as E. coli provides non-glycosylated molecules.
  • Functional mutant analogs of mammalian TNFR having inactivated N-glycosylation sites can be produced by oligonucleotide synthesis and ligation or by site-specific mutagenesis techniques. These analog proteins can be produced in a homogeneous, reduced- carbohydrate form in good yield using yeast expression systems.
  • operably linked means contiguous and, in the case of secretory leaders, contiguous and in reading frame.
  • Structural elements intended for use in yeast expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell.
  • recombinant protein may include an N-terminal methionine residue. This residue may optionally be subsequently cleaved from the expressed recombinant protein to provide a final product.
  • ORGANISM Homo sapiens (G) CELL TYPE: Fibroblast (H) CELL LINE: WI-26 VA4 28

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Procédé de traitement de maladies inflammatoires dépendantes du TNF chez un mammifère, consistant à administrer un antagoniste du TNF, tel qu'un récepteur de TNF soluble.
EP93921562A 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists. Withdrawn EP0620739A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94623692A 1992-09-15 1992-09-15
US946236 1992-09-15
PCT/US1993/008666 WO1994006476A1 (fr) 1992-09-15 1993-09-14 Procede de traitement de l'inflammation dependante du facteur necrosant des tumeurs malignes (tnf) a l'aide d'antagonistes dudit tnf

Publications (2)

Publication Number Publication Date
EP0620739A1 true EP0620739A1 (fr) 1994-10-26
EP0620739A4 EP0620739A4 (en) 1997-01-15

Family

ID=25484181

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93921562A Withdrawn EP0620739A4 (en) 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.

Country Status (8)

Country Link
EP (1) EP0620739A4 (fr)
JP (1) JPH07504203A (fr)
KR (1) KR100232688B1 (fr)
AU (1) AU670125B2 (fr)
CA (1) CA2123593C (fr)
NO (1) NO941780L (fr)
NZ (1) NZ256293A (fr)
WO (1) WO1994006476A1 (fr)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
ATE242322T1 (de) * 1992-03-30 2003-06-15 Immunex Corp Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
HUT76666A (en) * 1994-07-22 1997-10-28 Hoffmann La Roche Pharmaceutical compositions comprising a chimaeric tnf binding protein
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
JPH11500308A (ja) * 1995-02-03 1999-01-12 ジー．ディー．サール アンド カンパニー 新規ｃ−ＭＰＬリガンド
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
DE69525181T2 (de) * 1995-07-14 2002-08-14 Applied Research Systems Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
EP0910413A2 (fr) * 1996-05-08 1999-04-28 F. Hoffmann-La Roche Ag TRAITEMENT DE L'ASTHME PAR TNFR-Ig
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
EP1352656A3 (fr) * 1996-12-06 2004-02-04 Amgen Inc. Thérapie combinatoire utilisant une protèine de liaison du facteur de nécrose tumorale (TNF) dans le traitement de maladies induites par le TNF
CA2273850A1 (fr) 1996-12-06 1998-06-11 Amgen Inc. Therapie combinatoire utilisant une proteine de liaison du facteur de necrose tumorale (tnf) dans le traitement de maladies induites par le tnf
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP1170017A1 (fr) * 1997-05-12 2002-01-09 The Kennedy Institute Of Rheumatology Utilisation du facteur de nécrose tumorale alpha (TNF-alpha) et du facteur de croissance des cellules endothéliales (VEGF) pour la préparation d'une composition thérapeutique
AU8492598A (en) * 1997-07-17 1999-02-10 Regents Of The University Of Michigan, The Methods and compositions for tumor reduction
JP2002530273A (ja) * 1998-07-13 2002-09-17 パーカシュ エス． ギル， 脈管形成および腫瘍増殖の新規インヒビター
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DE69937070D1 (de) * 1998-11-05 2007-10-18 Omeros Corp Spüllösung und verfahren zur schmerzlinderung und entzündungshemmung
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
EP1022027A1 (fr) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Antagonistes du TNF (Tumor necrosis factor) et leurs utilisations contre l'endometriose
EP1165116A1 (fr) * 1999-04-02 2002-01-02 Immunex Corporation Utilisation d'un recepteur du facteur de necrose tumorale soluble dans le traitement de l'insuffisance cardiaque
EP1939300A1 (fr) * 1999-05-28 2008-07-02 Targeted Genetics Corporation Procédés et compositions pour diminuer le niveau de facteur de nécrose de tumeur (TNF) pour des troubles associés au TNF
US6537540B1 (en) * 1999-05-28 2003-03-25 Targeted Genetics Corporation Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
CN101850120A (zh) * 1999-07-21 2010-10-06 奥默罗斯公司 用于抑制疼痛,炎症和软骨退化的溶液及方法
AU6517800A (en) 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
MXPA02001264A (es) 1999-08-04 2002-07-22 Amgen Inc Fhm, nuevo miembro de la familia de supergenes de ligando de factor de necrosis tumoral.
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
CA2868614A1 (fr) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
EP2298810A3 (fr) 2002-07-19 2011-08-03 Abbott Biotechnology Ltd Traitement des troubles associés au TND alpha
JP2006512900A (ja) * 2002-08-16 2006-04-20 ワイス Ｒａｇｅ関連疾患の治療用組成物及び方法
CN1694958A (zh) * 2002-09-13 2005-11-09 昆士兰大学 以密码子翻译效率为基础的基因表达系统
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
JP4980048B2 (ja) * 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
AU2004279742A1 (en) * 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
KR101027427B1 (ko) * 2004-11-12 2011-04-11 젠코어 인코포레이티드 ＦcRn에 대하여 증가된 결합력을 갖는 Ｆc 변이체
AU2006230419A1 (en) * 2005-03-31 2006-10-05 Targeted Genetics Corporation Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
CA2903138A1 (fr) 2005-05-16 2006-11-23 Abbvie Biotechnology Ltd. Utilisation d'un inhibiteur du tnf alpha pour le traitement de la polyarthrite erosive
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP1948235B1 (fr) 2005-11-01 2013-08-28 AbbVie Biotechnology Ltd Méthodes de détermination de l'efficacité de l'adalimumab chez des sujets ayant une spondylarthrite ankylosante utilisant ctx-ii et mmp3 comme biomarqueurs
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
AU2007309650A1 (en) * 2006-02-08 2008-05-02 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
WO2007109686A2 (fr) 2006-03-20 2007-09-27 University Of Pittsburgh Immunomodulation de conditions inflammatoires en utilisant la protéine 1 apparentée à la follistatine et des agents se liant à celle-ci
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
SG170837A1 (en) 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
CA2564435A1 (fr) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methodes de controle et de traitement des troubles intestinaux
EP2007426A4 (fr) 2006-04-10 2010-06-16 Abbott Biotech Ltd Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
EP2666479A3 (fr) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de l'arthrite rhumatoïde juvénile
EP2043711A4 (fr) 2006-06-30 2017-08-30 AbbVie Biotechnology Ltd Dispositif d'injection automatique
EP2061802A1 (fr) * 2006-08-28 2009-05-27 Ares Trading S.A. Procédé de purification de protéines fc-hybrides
JP2010501622A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
FI2061803T4 (fi) 2006-08-28 2023-03-14 Process for the purification of fc-containing proteins
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20090083958A (ko) 2006-10-20 2009-08-04 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
US8092998B2 (en) 2007-05-31 2012-01-10 Abbott Laboratories Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
WO2008154543A2 (fr) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Procédés de traitement de l'arthrite idiopathique juvénile
MX2009013194A (es) 2007-06-14 2010-03-30 Galactica Pharmaceuticals Inc Proteinas de fusion del receptor para productos finales de glicacion avanzada.
EP2072527A1 (fr) 2007-12-21 2009-06-24 Altonabiotec AG Procédé et système pour fournir des services de communications sur un terminal mobile, et terminal mobile
US8658379B2 (en) 2008-01-29 2014-02-25 University of Pittsburgh—of the Commonwealth System of Higher Education Follistatin-like protein-1 as a biomarker for sepsis
AU2009280913A1 (en) * 2008-08-12 2010-02-18 Avesthagen Limited An expression vector and a method thereof
CA2750155A1 (fr) 2008-12-30 2010-07-08 Centocor Ortho Biotech Inc. Marqueurs seriques predisant la reponse clinique a des anticorps anti-tnf.alpha. chez les patients souffrant de spondylarthrite ankylosante
MX2011011541A (es) 2009-04-29 2012-02-28 Abbott Biotech Ltd Dispositivo de inyeccion automatico.
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
BR112012013330A2 (pt) 2009-12-02 2017-03-28 Acceleron Pharma Inc composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
US20110150891A1 (en) 2009-12-16 2011-06-23 Philip Bosch Methods of Treating Interstitial Cystitis
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EA201891433A3 (ru) 2010-01-15 2019-02-28 Кирин-Эмджен, Инк. Состав антитела и терапевтические режимы
JP2013518590A (ja) 2010-02-02 2013-05-23 アボツト・バイオテクノロジー・リミテツド ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
RU2695703C2 (ru) 2010-04-21 2019-07-25 Эббви Байотекнолоджи Лтд. Носимое устройство для автоматической инъекции для управляемой подачи терапевтических агентов
WO2011146727A1 (fr) 2010-05-19 2011-11-24 Philip Bosch Méthodes de traitement de la cystite interstitielle
LT2575884T (lt) 2010-06-03 2018-09-25 Abbvie Biotechnology Ltd Panaudojimai ir kompozicijos, skirti pūlingo hidradenito (hs) gydymui
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
WO2012019099A2 (fr) 2010-08-05 2012-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Protéine 1 analogue à la follistatine utilisable en tant que biomarqueur des troubles inflammatoires
BR112013018905B1 (pt) 2011-01-24 2021-07-13 Abbvie Biotechnology Ltd Dispositivos de injeção automática que têm superfícies de pega sobremoldadas.
CA2829773A1 (fr) 2011-03-18 2012-09-27 Abbvie Inc. Systemes, dispositifs et procedes pour assembler des dispositifs a injection automatique et des sous-ensembles leur correspondant
ES2669198T5 (es) 2011-03-29 2021-07-20 Abbvie Inc Despliegue de envolvente mejorado en dispositivos de inyección automáticos
EP3020428A1 (fr) 2011-04-21 2016-05-18 AbbVie Inc. Dispositif d'injection automatique portable pour l'administration contrôlée d'agents thérapeutiques
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
EP2718328A4 (fr) 2011-06-08 2014-12-24 Acceleron Pharma Inc Compositions et procédés pour augmenter la demi-vie sérique
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
AR088383A1 (es) 2011-10-18 2014-05-28 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles
KR101525919B1 (ko) * 2012-05-11 2015-06-03 가톨릭대학교 산학협력단 자가면역 질환 예방 및 치료를 위한 ｔｎｆｒ２를 기반으로 하는 이중 항체
AU2013315750B9 (en) 2012-09-11 2018-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
KR102530900B1 (ko) 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
WO2015198320A1 (fr) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Procédés de purification d'anticorps
WO2016102328A1 (fr) 2014-12-22 2016-06-30 Ares Trading S.A. Composition pharmaceutique liquide
EP3078675A1 (fr) 2015-04-10 2016-10-12 Ares Trading S.A. Régime de dosage à induction pour le traitement des maladies liées au tnf alpha
EP3440113A1 (fr) 2016-04-08 2019-02-13 Gilead Sciences, Inc. Compositions et méthodes de traitement du cancer, de maladies inflammatoires et de maladies autoimmunes
EP3257866A1 (fr) 2016-06-17 2017-12-20 Academisch Medisch Centrum Anticorps anti-tnf modifiés et leur utilisation dans le traitement de la maladie intestinale inflammatoire
KR102616436B1 (ko) 2016-12-14 2023-12-27 비오라 쎄라퓨틱스, 인크. Tnf 저해제로의 위장관 질환의 치료
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
EP3810095A1 (fr) 2018-06-20 2021-04-28 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur du tnf
JP2021529780A (ja) 2018-07-03 2021-11-04 ノバルティス アーゲー Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
CA3110891A1 (fr) 2018-08-29 2020-03-05 Regeneron Pharmaceuticals, Inc. Methodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoide
US11498969B2 (en) 2019-01-31 2022-11-15 Sanofi Biotechnology Compositions and methods for treating juvenile idiopathic arthritis
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
JP2023554200A (ja) 2020-12-09 2023-12-26 エイチケー イノ．エヌ コーポレーション 抗ＯＸ４０Ｌ抗体、抗ＯＸ４０Ｌ及び抗ＴＮＦαの二重特異性抗体、並びにこれらの用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003553A1 (fr) * 1989-09-05 1991-03-21 Immunex Corporation RECEPTEURS DES FACTEURS NECROSE TUMORALE α et $g(b)
WO1992013095A1 (fr) * 1991-01-18 1992-08-06 Synergen, Inc. Procedes pour traiter les maladies induites par facteur de necrose tumorale

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
CA2145192A1 (fr) * 1992-09-22 1994-03-31 Gail Underiner Nouveaux composes renfermant de l'epoxyde

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003553A1 (fr) * 1989-09-05 1991-03-21 Immunex Corporation RECEPTEURS DES FACTEURS NECROSE TUMORALE α et $g(b)
WO1992013095A1 (fr) * 1991-01-18 1992-08-06 Synergen, Inc. Procedes pour traiter les maladies induites par facteur de necrose tumorale

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
1992 MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY (FASEB), PART I, ANAHEIM, CALIFORNIA, USA, APRIL 5-9, 1992. FASEB (FED AM SOC EXP BIOL) J 6 (4). 1992. A1123, XP002015786 MOHLER K M ET AL: "IMMUNOTHERAPEUTIC POTENTIAL OF SOLUBLE CYTOKINE RECEPTORS IN INFLAMMATORY DISEASE." *
KEYSTONE SYMPOSIUM ON CYTOKINES AND CYTOKINE RECEPTORS: FROM CLONING TO THE CLINIC, KEYSTONE, COLORADO, USA, JANUARY 31-FEBRUARY 7, 1993. J CELL BIOCHEM SUPPL 0 (17 PART B). 1993. 56, XP002015787 MOHLER K M ET AL: "COUNTERACTING THE EFFECTS OF TNF WITH SOLUBLE TNF RECEPTORS." *
See also references of WO9406476A1 *

Also Published As

Publication number Publication date
CA2123593C (fr) 2000-03-14
WO1994006476A1 (fr) 1994-03-31
AU670125B2 (en) 1996-07-04
NZ256293A (en) 1997-06-24
NO941780D0 (no) 1994-05-11
EP0620739A4 (en) 1997-01-15
AU4920993A (en) 1994-04-12
NO941780L (no) 1994-07-15
JPH07504203A (ja) 1995-05-11
KR100232688B1 (ko) 1999-12-01
CA2123593A1 (fr) 1994-03-31

Similar Documents

Publication Publication Date Title
AU670125B2 (en) Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5605690A (en) Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US6201105B1 (en) Tumor necrosis factor receptor polypeptides recombinant P75 (Type II)
EP0418014B1 (fr) Récepteurs pour le facteur de nécrose de tumeur alpha et beta
CA2065346C (fr) Recepteurs .alpha. et .beta. de facteur de necrose tumorale
US5945397A (en) Purified p75 (type II) tumor necrosis factor receptor polypeptides
EP0460846B1 (fr) Récepteurs de type II de l'interleukine 1
AU646695B2 (en) Isolated viral protein cytokine antagonists
AU647566B2 (en) Leukemia inhibitory factor receptors
IE83679B1 (en) Type II interleukin-1 receptors
NZ251820A (en) Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
US7700318B2 (en) Chimeric polypeptide and use thereof
IE911108A1 (en) Isolated Viral Protein Cytokine Antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940518

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19961127

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19970228

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980103